Business Context and Reporting Period
This Form 8-K is a current report filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on March 24, 2021, regarding events occurring on March 23 and 24, 2021. The filing addresses a private placement of common stock and significant developments concerning a proposed business combination with Pixium Vision SA.
Key Financial Metrics and Transactions
- Private Placement Proceeds: The Company announced a private placement expected to generate gross proceeds of $27.9 million.
- Issuance Details: 4,650,000 shares of common stock are to be issued at a price of $6.00 per share.
- Expected Closing Date: March 26, 2021.
- Termination Payment: The Company agreed to pay Hudson Bay Capital Management (HB) $1,350,000 plus $50,000 in legal fees to terminate a prior term sheet.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity ratios.
Material Changes and Contingencies
Conflict with Pixium Vision SA
The Company entered into a Memorandum of Understanding (MOU) with Pixium Vision SA on January 5, 2021, which restricted the issuance of new equity without Pixium's consent. Pixium asserted on March 23, 2021, that the Private Placement constitutes a material breach of the MOU and refused consent.
- Legal Risk: The consummation of the Private Placement without consent may lead to legal proceedings.
- Termination Fee: Pixium may seek to terminate the MOU and claim a termination fee of up to $1 million.
- Transaction Status: Certain closing conditions for the Pixium business combination may not be satisfied.
Resolution with Hudson Bay Capital Management
To facilitate the Private Placement, the Company terminated an exclusivity term sheet with Hudson Bay Capital Management (HB) entered into on March 7, 2021. HB waived its rights to a $2.5 million payment or 50% participation in the financing in exchange for the $1.4 million settlement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the use of proceeds and the business combination with Pixium. Management explicitly states that no assurance can be made regarding the resolution of the disagreement with Pixium.
- Primary Risks: Failure of the financing or business combination to close; legal claims and costs related to the MOU breach; potential termination of the Pixium transaction.
- Other Risks: Changes in laws/regulations, economic factors, and the impact of COVID-19.
- Shareholder Action: Shareholders are advised to await the preliminary and definitive proxy statements for the proposed business combination before voting.
Investor Verification Checklist
- Verify the final closing status of the $27.9 million private placement and whether Pixium consent was obtained or the MOU was terminated.
- Monitor for any legal filings or announcements regarding the potential $1 million termination fee claim by Pixium.
- Review the upcoming proxy statement for details on the proposed business combination with Pixium Vision SA.
- Confirm the actual cash proceeds received after deducting placement offering expenses and the $1.4 million payment to Hudson Bay Capital Management.